Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's forecasts. The revenue forecast for this year has experienced a facelift, with the analysts now much more optimistic on its sales pipeline.

Following the upgrade, the latest consensus from Agios Pharmaceuticals' ten analysts is for revenues of US$184m in 2026, which would reflect a substantial 87% improvement in sales compared to the last 12 months. Losses are presumed to reduce, shrinking 17% per share from last year to US$5.71. Yet prior to the latest estimates, the analysts had been forecasting revenues of US$120m and losses of US$6.26 per share in 2026. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a sizeable increase to their revenue forecasts while also reducing the estimated loss as the business grows towards breakeven.

The consensus price target rose 7.1% to US$45.38, with the analysts encouraged by the higher revenue and lower forecast losses for this year.

Of course, another way to look at these forecasts is to place them into context against the industry itself. The analysts are definitely expecting Agios Pharmaceuticals' growth to accelerate, with the forecast 248% annualised growth to the end of 2026 ranking favourably alongside historical growth of 52% per annum over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 22% per year. Factoring in the forecast acceleration in revenue, it's pretty clear that Agios Pharmaceuticals is expected to grow much faster than its industry.

The Bottom Line

The most important thing here is that analysts reduced their loss per share estimates for this year, reflecting increased optimism around Agios Pharmaceuticals' prospects. Fortunately, analysts also upgraded their revenue estimates, and our data indicates sales are expected to perform better than the wider market. There was also an increase in the price target, suggesting that there is more optimism baked into the forecasts than there was previously. Given that analysts appear to be expecting substantial improvement in the sales pipeline, now could be the right time to take another look at Agios Pharmaceuticals.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have estimates - from multiple Agios Pharmaceuticals analysts - going out to 2028, and you can see them free on our platform here.

Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies backed by insiders.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.